RegenxBio Inc - Company Profile
Powered by
All the data and insights you need on RegenxBio Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date RegenxBio Inc Strategy Report
- Understand RegenxBio Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on RegenxBio Inc patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
US20220280608A1 | Application | TREATMENT OF DIABETIC RETINOPATHY WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FAB | A61B5/01; A61K38/1866; A61P27/02; C07K16/22; C07K2317/41; C07K2317/55 | September 08, 2022 |
US20220275358A1 | Application | METHODS OF SIZE EXCLUSION CHROMATOGRAPHY FOR THE CHARACTERIZATION OF RECOMBINANT ADENO-ASSOCIATED VIRUS COMPOSITIONS | B01D15/34; C12N15/101; C12N2750/14151; C12N7/00; C12Q1/6851; C12Q1/701; G01N1/44; G01N30/74 | September 01, 2022 |
IL294636A | Application | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells | A61K31/436; A61K31/573; A61K31/711; A61K38/465; A61K45/06; A61K48/005; A61K48/0075; A61K48/0083; A61K9/0019; A61K9/0085; A61P3/00; A61P43/00; C12N9/16; C12Y301/06013; G01N2333/916; G01N2400/40 | September 01, 2022 |
IL294625A | Application | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) | A61K31/365; A61K31/436; A61K31/573; A61K38/47; A61K45/06; A61K48/0016; A61K48/005; A61K48/0075; A61P25/00; C12N15/85; C12N2750/14143; C12N9/2402; C12Y302/01076 | September 01, 2022 |
IL294638A | Application | Treatment of mucopolysaccharidosis iva | A01K2217/075; A01K2227/105; A01K2267/0306; A61K48/0058; C07K2319/33; C12N15/86; C12N2750/14143; C12N2800/22; C12N2830/008; C12N2830/15; C12Y301/06004 | September 01, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer